Cargando…

Physiologically Based Pharmacokinetic Modelling to Predict Imatinib Exposures in Cancer Patients with Renal Dysfunction: A Case Study

Imatinib is mainly metabolised by CYP3A4 and CYP2C8 and is extensively bound to α-acid glycoprotein (AAG). A physiologically based pharmacokinetic (PBPK) model for imatinib describing the CYP3A4-mediated autoinhibition during multiple dosing in gastrointestinal stromal tumor patients with normal ren...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rowland Yeo, Karen, Hatley, Oliver, Small, Ben G., Johnson, Trevor N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386083/ https://www.ncbi.nlm.nih.gov/pubmed/37514108 http://dx.doi.org/10.3390/pharmaceutics15071922

Ejemplares similares

Increasing application of pediatric physiologically based pharmacokinetic models across academic and industry organizations
por: Johnson, Trevor N., et al.
Publicado: (2022)

A best practice framework for applying physiologically‐based pharmacokinetic modeling to pediatric drug development
por: Johnson, Trevor N., et al.
Publicado: (2021)

Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effect of Renal Impairment on the Pharmacokinetics of Olanzapine and Samidorphan Given in Combination
por: Sun, Lei, et al.
Publicado: (2020)

Development of physiologically‐based pharmacokinetic models for standard of care and newer tuberculosis drugs
por: Humphries, Helen, et al.
Publicado: (2021)

Physiologically‐Based Pharmacokinetic Modeling for Predicting Drug Interactions of a Combination of Olanzapine and Samidorphan
por: Sun, Lei, et al.
Publicado: (2020)

Using physiologically‐based pharmacokinetic modeling for predicting the effects of hepatic impairment on the pharmacokinetics of olanzapine and samidorphan given as a combination tablet
por: Sun, Lei, et al.
Publicado: (2021)

Addressing drug safety of maternal therapy during breastfeeding using physiologically‐based pharmacokinetic modeling
por: Pan, Xian, et al.
Publicado: (2022)

A Physiologically Based Pharmacokinetic Model to Predict Determinants of Variability in Epirubicin Exposure and Tissue Distribution
por: Ansaar, Radwan, et al.
Publicado: (2023)

Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development
por: Jones, HM, et al.
Publicado: (2013)

Physiologically‐Based Pharmacokinetic Models as Enablers of Precision Dosing in Drug Development: Pivotal Role of the Human Mass Balance Study
por: Rowland Yeo, Karen, et al.
Publicado: (2020)

An Integrated Approach for Assessing the Impact of Renal Impairment on Pharmacokinetics of Drugs in Development: Pivotal Role of PBPK Modelling
por: Rowland Yeo, Karen, et al.
Publicado: (2021)

Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic Model
por: Almond, Lisa M., et al.
Publicado: (2016)

Risk–Benefit Assessment of Ethinylestradiol Using a Physiologically Based Pharmacokinetic Modeling Approach
por: Ezuruike, Udoamaka, et al.
Publicado: (2018)

Predictive Performance of Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling of Renally Cleared Drugs in Children
por: Zhou, W, et al.
Publicado: (2016)

Physiologically based pharmacokinetic modeling of levetiracetam to predict the exposure in hepatic and renal impairment and elderly populations
por: Shen, Chaozhuang, et al.
Publicado: (2023)

A Physiologically Based Pharmacokinetic Model to Predict the Impact of Metabolic Changes Associated with Metabolic Associated Fatty Liver Disease on Drug Exposure
por: Newman, Elise M., et al.
Publicado: (2022)

Application of Physiologically Based Pharmacokinetic Modeling to Predict Maternal Pharmacokinetics and Fetal Exposure to Oxcarbazepine
por: He, Lixia, et al.
Publicado: (2022)

Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment
por: Wu, Wanhong, et al.
Publicado: (2021)

Prediction for Plasma Trough Concentration and Optimal Dosing of Imatinib under Multiple Clinical Situations Using Physiologically Based Pharmacokinetic Modeling
por: Gao, Dongmei, et al.
Publicado: (2023)

Development of a physiologically based pharmacokinetic (PBPK) population model for Chinese elderly subjects
por: Cui, Cheng, et al.
Publicado: (2021)

Physiologically based pharmacokinetic modeling for predicting irinotecan exposure in human body
por: Fan, Yingfang, et al.
Publicado: (2017)

The Effect of Apigenin on Pharmacokinetics of Imatinib and Its Metabolite N-Desmethyl Imatinib in Rats
por: Liu, Xian-yun, et al.
Publicado: (2013)

A Physiologically-Based Pharmacokinetic Framework for Prediction of Drug Exposure in Malnourished Children
por: Sjögren, Erik, et al.
Publicado: (2021)

The Future of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure in Pregnant Women
por: Vinks, A A
Publicado: (2013)

Prediction of pyrotinib exposure based on physiologically-based pharmacokinetic model and endogenous biomarker
por: Zhang, Miao, et al.
Publicado: (2022)

Physiologically Based Pharmacokinetic Modeling Approaches for Patients With SARS‐CoV‐2 Infection: A Case Study With Imatinib
por: Adiwidjaja, Jeffry, et al.
Publicado: (2022)

Application of physiologically based pharmacokinetic modeling to understand real‐world outcomes in patients receiving imatinib for chronic myeloid leukemia
por: Adattini, Josephine A., et al.
Publicado: (2023)

Pharmacokinetics Interaction between Imatinib and Genistein in Rats
por: Wang, Zhe, et al.
Publicado: (2015)

Predicting the systemic exposure and lung concentration of nafamostat using physiologically-based pharmacokinetic modeling
por: Jeong, Hyeon-Cheol, et al.
Publicado: (2022)

Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in Paediatrics
por: Adiwidjaja, Jeffry, et al.
Publicado: (2020)

Combining Therapeutic Drug Monitoring and Pharmacokinetic Modelling Deconvolutes Physiological and Environmental Sources of Variability in Clozapine Exposure
por: Wills, Kenneth H., et al.
Publicado: (2021)

Physiologically-Based Pharmacokinetic (PBPK) Modeling and Simulations Principles, Methods, and Applications in the Pharmaceutical Industry
por: Rowland, M
Publicado: (2013)

Physiologically Based Pharmacokinetics Modeling in the Neonatal Population—Current Advances, Challenges, and Opportunities
por: Dinh, Jean, et al.
Publicado: (2023)

Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide
por: Rezaï, Keyvan, et al.
Publicado: (2007)

Prediction of CYP‐mediated DDIs involving inhibition: Approaches to address the requirements for system qualification of the Simcyp Simulator
por: Kilford, Peter J., et al.
Publicado: (2022)

Pharmacokinetics of metoclopramide in calves with renal dysfunction
por: TAKAYASU, Mariko, et al.
Publicado: (2014)

Application of Physiologically Based Pharmacokinetic Modeling to Predict Acetaminophen Metabolism and Pharmacokinetics in Children
por: Jiang, X-L, et al.
Publicado: (2013)

Application of Physiologically Based Pharmacokinetic Modeling to Predict Pharmacokinetics in Healthy Japanese Subjects
por: Matsumoto, Yuki, et al.
Publicado: (2018)

Predicting Resolvin D1 Pharmacokinetics in Humans with Physiologically‐Based Pharmacokinetic Modeling
por: Yellepeddi, Venkata K., et al.
Publicado: (2020)

Comparison of the Use of a Physiologically Based Pharmacokinetic Model and a Classical Pharmacokinetic Model for Dioxin Exposure Assessments
por: Emond, Claude, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_4mg44jg65b3ugdnkmhqgi2rq8p